Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Abzena a play on the biologics revolution, says City broker

The subsector in which Abezena is active in (monoclonal antibody and conjugated monoclonal antibodies) could expand to US$180bn, Peel Hunt’s research suggests
Abzena a play on the biologics revolution, says City broker
The company works with 18 of the top 25 biopharma companies in the US and the EU

Abzena PLC (LON:ABZA) is a “diverse play” on the biologics revolution. That, at least is the conclusion of Miles Dixon, healthcare analyst at the City broker Peel Hunt.

The market for biologics, which covers disciplines as diverse as vaccines, allergenics and monoclonal antibodies, is expected to grow to US$330bn by 2022.

READ: Abzena moves UK operations to new Cambridge facility; signs lease for new San Diego base

That’s a huge opportunity for the company, which has developed technology that helps biopharmaceutical companies improve drug candidates.

Where the company’s technology is used to enhance or enable a treatment, this normally results in milestone payments and/or royalties on the sale of an approved product.


It currently has 14 ‘Abzena Inside’ collaboration deals with drug developers at different phases of development.

“This model creates a dual strategy for revenue generation and has the potential to provide significant cash to the business in future years as milestones fall due or the products reach the market,” said analyst Dixon.  

He believes the shares are worth 42p each, with the services part of the business valued at 19p a share and pharmaceuticals candidates pencilled in to his model at 23p. Currently, the shares are changing hands for 26p each, giving Abzena a market capitalisation of £47mln.

WATCH: Growth & investment strategy starting to bear fruit for Abzena PLC

The hybrid model, Dixon believes, “allows investors to avoid the risk of investing in single-candidate pipeline stories but benefit from the biologics revolution of antibody-derived therapies”.

Abzena was created in 2013 when Polytherics, a business founded by Imperial College London and the University of London’s School of Pharmacy, paid £11.5mln for a company called Antitope. It floated on AIM a year later before acquiring two operations in the US – PacificGMP and The Chemistry Research Solution.

Today, it offers a broad portfolio of services helping pharma companies and universities select, develop and manufacture antibodies and proteins. It has three main units: chemistry research, biology research and drug manufacturing services. And it works with 18 of the top 25 biopharma companies in the US and EU.

Abzena Inside

The ‘Abzena Inside’ portfolio includes a tie-up with Gilead Sciences Inc, (NASDAQ:GILD)  a giant of the biotech world.

As mentioned earlier, the firm is tapping into a large and fertile market.

Big pharma is currently looking for replacements for former blockbuster therapies.

However, the flow of these one-size-fits-all treatments for ailments such as high cholesterol, cancer and asthma that have supported the growth of these behemoths to date has slowed to a trickle.

Instead, the focus has turned to personalised medicines, recognising that physiologically no two humans are alike.

This has spawned a series of new drugs that find their origins in bio-medical research.

As mentioned earlier, in five years, the biologics market could be worth a whopping US$330bn if it carries on at its current trajectory.

Rich sub-sector

The subsector in which Abzena is active in (monoclonal antibody and conjugated monoclonal antibodies) could expand to US$180bn, Peel Hunt’s research suggests.

The broker bases its investment thesis on the growth profile of the market it serves, pointing out the company is set for renewed growth after a heavy investment phase.

The diversified portfolio helps mitigate some of the risk, while the business also has a “rich heritage of high profile clients”, analyst Dixon pointed out.

“Abzena is an undervalued CRDMO [research, development and manufacturing] business that delivers robust revenues from its specialist services at the point of delivery,” he added.

“The company benefits from extensive repeat business (c80% by revenue in 2017) as clients stay with Abzena throughout the development cycle for therapeutics.

“Furthermore, Abzena has upside potential from future royalties secured on a number of its co-developed products – the Abzena Inside portfolio.”

View full ABZA profile View Profile

Abzena PLC Timeline

Related Articles

tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
September 25 2018
A decision on whether or not Motif can start marketing its next-generation antibiotic in the US is due by mid-February
March 19 2018
The group has received key permits to allow cannabis - flowers and oils - to be imported into Australia from Aurora Cannabis Inc

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use